Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CLDX 
Celldex Therapeutics Inc (CLDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/17/2025: CLDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $53.14
1 Year Target Price $53.14
| 10 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.7% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.70B USD | Price to earnings Ratio - | 1Y Target Price 53.14 |
Price to earnings Ratio - | 1Y Target Price 53.14 | ||
Volume (30-day avg) 14 | Beta 1.14 | 52 Weeks Range 14.40 - 29.05 | Updated Date 11/16/2025 |
52 Weeks Range 14.40 - 29.05 | Updated Date 11/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.8985 | Actual -1.01 |
Profitability
Profit Margin - | Operating Margin (TTM) -9859.22% |
Management Effectiveness
Return on Assets (TTM) -21.77% | Return on Equity (TTM) -32.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1117846478 | Price to Sales(TTM) 653.25 |
Enterprise Value 1117846478 | Price to Sales(TTM) 653.25 | ||
Enterprise Value to Revenue 430.11 | Enterprise Value to EBITDA -17.34 | Shares Outstanding 66449471 | Shares Floating 53249948 |
Shares Outstanding 66449471 | Shares Floating 53249948 | ||
Percent Insiders 0.19 | Percent Institutions 110.65 |
Upturn AI SWOT
Celldex Therapeutics Inc
Company Overview
History and Background
Celldex Therapeutics Inc. was founded in 1991. It is a biopharmaceutical company focused on developing and commercializing innovative immunotherapies for cancer and other diseases. Over time, Celldex has evolved from a drug delivery company to a leader in antibody-based therapeutics.
Core Business Areas
- Immunotherapy Development: Celldex focuses on developing antibody-based therapies that harness the body's immune system to fight cancer. These therapies target specific molecules on cancer cells to stimulate an immune response.
- Proprietary Technology Platform: The company has a proprietary technology platform for identifying and developing novel antibodies and other immunotherapeutic agents.
Leadership and Structure
Anthony Marucci is the Co-founder, President and Chief Executive Officer. The company has a typical structure of a publicly traded biopharmaceutical firm, with a board of directors and various departments (research, development, clinical, commercial, etc.).
Top Products and Market Share
Key Offerings
- Varlilumab (anti-CD27 antibody): An investigational immunotherapy targeting the CD27 receptor to activate immune cells. It is currently in clinical trials for various cancers. Market share data is not applicable as it is not yet approved for sale. Competitors include companies developing similar immuno-oncology therapies (e.g., Merck (MRK) with Keytruda, Bristol Myers Squibb (BMY) with Opdivo).
- CDX-0159 (anti-KIT antibody): An investigational immunotherapy targeting KIT, being developed for chronic urticaria. Market share data is not applicable as it is not yet approved for sale. Competitors in chronic urticaria include Novartis (NVS) and Genentech (Roche) with Xolair.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investments in research and development. Immunotherapy is a major area of focus, with many companies developing new therapies to treat cancer and other diseases.
Positioning
Celldex is a smaller player in the immunotherapy market, focusing on novel antibody-based therapies. Its competitive advantage lies in its proprietary technology platform and its focus on specific targets that are not yet widely addressed by other companies.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapy is estimated to be over $100 billion. Celldex is positioned to capture a portion of this market with its novel therapies, especially if varlilumab or CDX-0159 are approved. For chronic urticaria, market size for treatments are roughly 2 to 4 billion USD annually. Again, Celldex is positioned to capture a portion of this market
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Focus on novel antibody-based therapies
- Experienced management team
- Strong pipeline of clinical-stage product candidates
Weaknesses
- Reliance on clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- Lack of approved products
- High research and development costs
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- FDA approval of product candidates
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- NVS
- ROSY
Competitive Landscape
Celldex faces intense competition from larger pharmaceutical companies with more resources. However, its focus on novel targets and its proprietary technology platform give it a competitive edge in certain areas.
Growth Trajectory and Initiatives
Historical Growth: The company's growth has been primarily driven by clinical trial progress and partnerships.
Future Projections: Future growth depends on the success of its clinical trials and regulatory approvals. Analyst estimates vary depending on the perceived probability of success for their pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for varlilumab and CDX-0159 and exploring new therapeutic targets.
Summary
Celldex Therapeutics is a development-stage company focused on novel immunotherapy. It shows promise through its proprietary tech and focused pipeline, particularly varlilumab and CDX-0159. However, it faces financial constraints and relies heavily on positive clinical trial outcomes. It needs to be nimble to compete with larger pharmaceutical companies. Any negative clinical trial results will put the company in a very weak position.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and thorough due diligence. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celldex Therapeutics Inc
Exchange NASDAQ | Headquaters Hampton, NJ, United States | ||
IPO Launch date 2008-03-10 | Founder, President, CEO & Director Mr. Anthony S. Marucci M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 186 | Website https://www.celldex.com |
Full time employees 186 | Website https://www.celldex.com | ||
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.